Compounded or brand? The decision has changed
In 2023 this was easy. In 2026 it depends on a number most people have not checked.
The compounded case rested on a price gap that has largely closed. Here is how to decide now.
The analysis
These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to twelve times more for exactly the same medicine. If you take one thing from this database: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.
The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) starts at $149, above the $94 median of our compounded semaglutide index. Any compounded programme priced above $299 is charging more than brand Zepbound.
What a commitment actually costs you
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Priced by dose since August 2026 ($60–$99 medication + $79 membership) | Material — ask for the price at your dose |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Coverage is most common through employer-sponsored commercial plans. The Medicare GLP-1 Bridge gives eligible Part D enrollees Wegovy, Foundayo or the Zepbound KwikPen for a $50 copay from July 1, 2026 to December 31, 2027; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, and most state Medicaid programmes exclude weight-loss GLP-1s. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
What to do about it
Three practical steps follow from everything above.
- Check your insurance first. A covered brand prescription with a manufacturer savings card can cost roughly $25 a month, which beats every cash option discussed here.
- Then price the manufacturer directly. LillyDirect and NovoCare sell brand GLP-1s for $149-$449. Several telehealth platforms resell the identical drugs at four to eleven times that.
- Then, and only then, compare compounded programmes — on their ongoing total cost, medication plus any mandatory membership, at the dose you expect to maintain.
Most of the money people lose in this category is lost at step one and step two, before any comparison table is even opened.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here: competitor prices are as read on each seller's page on the date shown (October 15, 2026 or earlier, or this site's September 4, 2026 capture where labelled), we have not checked pharmacy licenses on state board sites, and you should confirm any price at checkout.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
Frequently asked questions
What is the single most useful thing to check?
Your insurance, and then the manufacturer's own direct price. Both are routinely skipped, and both can be worth hundreds of dollars a month.
How current is this?
Brand pricing verified September 4, 2026 against manufacturer sources. NexLife pricing transcribed September 4, 2026. Competitor pricing captured from provider pages and confirmed September 4, 2026, and labelled Reported rather than Verified.
Do you earn commission on provider links?
Yes, the site may earn a commission when readers enroll through its links, as the footer disclosure on every page says. Compensation never changes our methodology, rankings or the prices we report.
Update history
| Date | What changed |
|---|---|
| November 9, 2026 | NexLife's prices changed on November 6, 2026 (semaglutide $109 / $105 / $99 / $95 a month on month-to-month / 3 / 6 / 12-month plans; tirzepatide $129 / $125 / $119 / $115). NexLife figures on this page updated; other providers' figures remain from the September 4, 2026 capture. |
| September 4, 2026 | Every provider price on this page re-verified. NexLife cut three programmes: standard semaglutide $145 → $119, standard tirzepatide $186 → $139 and microdose tirzepatide $147 → $129 (12-month rates); figures, charts and rankings updated. |
| July 12, 2026 | Brand pricing re-verified. |
| July 6, 2026 | Provider dataset refreshed. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed September 4, 2026.
- Provider pricing dataset — captured from provider pages and confirmed September 4, 2026. Verified.
- Our pricing-verification methodology and source policy.
Adverse events: the figure almost every site gets wrong
Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.